Which option is NOT one of the three situations in which anticoagulant or antiplatelet therapy should NOT be interrupted?

Which option is NOT one of the three situations in which anticoagulant or antiplatelet therapy should NOT be interrupted?

• A. Cardioversion on anticoagulation
• B. Prosthetic heart valves or coronary stents
• C. Pulmonary embolism or deep vein thrombosis in last three months
• D. A patient treated for seasonal allergies

Answer: (D)

The key idea is that you don’t interrupt anticoagulant or antiplatelet therapy when there's a high risk of clot formation. Stopping these meds in high-thrombotic-risk situations can lead to dangerous clots, strokes, or device-related thrombosis, so continuing therapy is essential. Continuing anticoagulation around cardioversion is important because the goal is to prevent clot formation during the procedure and surrounding period. Mechanical heart valves and coronary stents create ongoing risk of thromboembolism or stent thrombosis, so ongoing antithrombotic therapy is required to protect against this. If a patient has a recent pulmonary embolism or deep vein thrombosis (within the last three months), there’s active clot risk and a renewed interruption could allow growth or recurrence of clots. The option about a patient treated for seasonal allergies doesn’t involve a heightened thrombotic risk that would necessitate keeping anticoagulant or antiplatelet therapy in place. It’s unrelated to the decisions about thrombosis prevention, so it’s not one of the scenarios where therapy must be maintained.

The key idea is that you don’t interrupt anticoagulant or antiplatelet therapy when there's a high risk of clot formation. Stopping these meds in high-thrombotic-risk situations can lead to dangerous clots, strokes, or device-related thrombosis, so continuing therapy is essential.

Continuing anticoagulation around cardioversion is important because the goal is to prevent clot formation during the procedure and surrounding period. Mechanical heart valves and coronary stents create ongoing risk of thromboembolism or stent thrombosis, so ongoing antithrombotic therapy is required to protect against this. If a patient has a recent pulmonary embolism or deep vein thrombosis (within the last three months), there’s active clot risk and a renewed interruption could allow growth or recurrence of clots.

The option about a patient treated for seasonal allergies doesn’t involve a heightened thrombotic risk that would necessitate keeping anticoagulant or antiplatelet therapy in place. It’s unrelated to the decisions about thrombosis prevention, so it’s not one of the scenarios where therapy must be maintained.